Related Experiment Video
Updated: Jun 7, 2026

Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache
Published on: July 29, 2021
Defining the pharmacologically intractable headache for clinical trials and clinical practice
Stephen D Silberstein1, David W Dodick, Starr Pearlman
1Department of Neurology, Thomas Jefferson University, Jefferson Headache Center, 111 S. 11th Street, Philadelphia, PA 19107, USA.
Abstract:
The terms refractory headache and intractable headache have been used interchangeably to describe persistent headache that is difficult to treat or fails to respond to standard and/or aggressive treatment modalities. A variety of definitions of intractability have been published, but as yet, an accepted/established definition is not available. To advance clinical and basic research in this population of patients, a universal and graded classification scheme of intractability is needed, and must include a definition of failure, to which and how many treatments the patient has failed, the level of headache-related disability, and finally, the intended intervention (clinical or research) and intensity of the intervention. This paper addresses each of these variables with the intent of providing a graded classification scheme that can be used in defining intractability for clinical practice interventions and clinical research initiatives.
Related Concept Videos
Clinical Trials: Overview
Analgesia and Pain Management
Pharmacodynamic Responses: Different Types
Clinical Trials
There are four phases in a clinical trial. A phase one...
Pharmacokinetic–Pharmacodynamic Relationship: Problems
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...

